Home » Stocks » RDUS

Radius Health, Inc. (RDUS)

Stock Price: $14.60 USD -0.25 (-1.65%)
Updated December 3, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 679.36M
Revenue (ttm) 231.53M
Net Income (ttm) -112.54M
Shares Out 46.49M
EPS (ttm) -2.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $14.60
Previous Close $14.84
Change ($) -0.25
Change (%) -1.65%
Day's Open 14.85
Day's Range 14.55 - 15.04
Day's Volume 228,167
52-Week Range 10.32 - 23.12

More Stats

Market Cap 679.36M
Enterprise Value 778.19M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 46.49M
Float n/a
EPS (basic) -2.43
EPS (diluted) -2.43
FCF / Share -1.16
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 7.63M
Short Ratio 18.11
Short % of Float n/a
Beta 1.08
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 2.93
PB Ratio n/a
Revenue 231.53M
Operating Income -87.53M
Net Income -112.54M
Free Cash Flow -54.00M
Net Cash -98.83M
Net Cash / Share -2.12
Gross Margin 68.26%
Operating Margin -37.81%
Profit Margin -48.60%
FCF Margin -23.32%
ROA -25.84%
ROE n/a
ROIC -30.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (8)

Buy 2
Overweight 0
Hold 6
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$20.25*
(38.75% upside)
Low
14.0
Current: $14.60
High
25.0
Target: 20.25
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue17399.2422.11------
Revenue Growth74.65%348.8%-------
Gross Profit15790.8120.78------
Operating Income-112-204-249-185-99.08-59.39-67.37-64.43-41.51
Net Income-133-221-254-183-102-62.48-60.69-69.13-42.48
Shares Outstanding46.0345.3643.8043.0739.6417.700.380.370.22
Earnings Per Share-2.89-4.88-5.80-4.24-2.56-4.04-203.91-225.710.06
Operating Cash Flow-82.41-205-207-140-87.10-48.35-45.02-43.16-35.90
Capital Expenditures--0.19-2.34-2.94-1.23-0.86--0.04-0.18
Free Cash Flow-82.41-205-209-143-88.33-49.20-45.02-43.20-36.07
Cash & Equivalents16123725333247310512.3022.65-
Total Debt202180166--24.3913.0120.81-
Net Cash / Debt-40.9057.2287.3333247380.88-0.701.85-
Assets21928746234048210812.7625.30-
Liabilities26122622033.1021.1844.95290226-
Book Value-42.2860.6324230746163.46-277-201-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Radius Health, Inc.
Country United States
Employees 383
CEO G. Kelly Martin

Stock Information

Ticker Symbol RDUS
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers-Specialty & Generic
Unique Identifier NASDAQ: RDUS
IPO Date June 6, 2014

Description

Radius Health, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS, an anabolic agent for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in phase 3 clinical study for the treatment of osteoporosis in men; abaloparatide transdermal patch, a short-wear-time patch, that is in phase 3 clinical study to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in phase 3 clinical study for the treatment of hormone receptor-positive breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator, which is in phase 1A clinical study to treat metastatic breast cancer. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; Guardant Health, Inc.; and Teijin Limited. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.